SELECT Analysis: Semaglutide and Liver Risk Markers
SELECT’s prespecified Nature Medicine analysis shows semaglutide reduced liver fibrosis risk and MACE in obese adults with ASCVD and no diabetes.
Key Takeaways
- The semaglutide SELECT analysis found roughly 20% reduction in MACE among patients at risk for liver fibrosis.
- Semaglutide lowered fatty liver index by approximately 28% over 104 weeks.
- MACE reduction reached 26% in the intermediate-risk subgroup (FIB-4 ≥1.3).
What did the semaglutide SELECT analysis assess?
The semaglutide SELECT analysis examined adults with obesity and established atherosclerotic cardiovascular disease but without diabetes. Researchers tracked major adverse cardiovascular events (MACE) and liver-related metrics—fatty liver index (FLI) and Fibrosis-4 (FIB-4) scores—over 104 weeks in a prespecified secondary analysis of the SELECT randomized, double-blind trial published in Nature Medicine in May 2026 (nature.com).
How much did semaglutide reduce MACE risk in fibrosis-risk subgroups?
Participants with FIB-4 ≥1.3 (intermediate fibrosis risk) experienced a 26% lower MACE rate with semaglutide versus placebo (hazard ratio 0.74; 95% CI 0.63–0.88; P = 0.0004) (nature.com). Those meeting age-adjusted thresholds—FIB-4 ≥1.3 for adults under 65 or ≥2.0 for those 65 and older—saw a 21% reduction (HR 0.79; 95% CI 0.63–0.98; P = 0.035) (nature.com).
Did semaglutide affect liver steatosis indicators?
Semaglutide treatment produced a 28% greater decrease in fatty liver index compared with placebo (HR 0.72; 95% CI 0.71–0.73; P < 0.0001), indicating improvement in hepatic steatosis risk factors (nature.com).
Were findings independent of weight loss or glycemic changes?
When researchers adjusted for changes in body weight and glycated hemoglobin, these factors showed negligible influence on the MACE reduction observed with semaglutide, suggesting the cardiovascular benefit extends beyond weight or glucose effects (nature.com).
FAQ
What does the semaglutide SELECT analysis show about MACE?
The semaglutide SELECT analysis shows that semaglutide lowered major adverse cardiovascular events by roughly 20–26% in adults with obesity, ASCVD, and no diabetes, particularly in those at risk for liver fibrosis based on FIB-4 scores.
Who were the patients in the semaglutide SELECT analysis?
Adults aged 45 years and older with BMI ≥27 kg/m², established atherosclerotic cardiovascular disease, and no diabetes (HbA₁c <6.5%), enrolled in the SELECT trial.
How was liver fibrosis risk assessed in the SELECT analysis?
The trial used noninvasive FIB-4 thresholds to define risk strata: ≥1.3 overall; age-adjusted ≥1.3 for adults under 65 or ≥2.0 for those 65 and older; and >2.67 irrespective of age.
Did semaglutide improve liver steatosis?
Semaglutide significantly reduced the fatty liver index by approximately 28% versus placebo over two years, indicating improved steatosis risk markers.
Was the MACE benefit solely due to weight loss?
The adjusted analyses suggest those changes did not fully account for the observed cardiovascular benefit. They do not establish a separate mechanism or prove that weight loss plays no role.
Note: This article is for general information and is not medical advice. Talk to a licensed clinician before using any peptide product.
Fatty liver index and FIB-4 are indirect markers. These findings do not establish that liver fibrosis itself regressed in every participant.